A phase I/IIa clinical trial to assess feasibility, safety and antitumor activity of autologous SLAMF7 CAR-T cells in multiple myeloma

Universitaetsklinikum Wuerzburg AöR1 site in 1 country33 target enrollmentJanuary 30, 2025

DrugsSLAMF7 C3 SLAMF7 C2 SLAMF7 CAR-T cells 3x10e5 cells/mL SLAMF7 CAR-T SLAMF7 CAR-T cells 1x10e4 cells/mL SLAMF7 CAR-T cells 1x10e6 cells/mL SLAMF7 C5 SLAMF7 CAR-T cells 1x10e4 cells/mL, SLAMF7 CAR-T cells 3x10e4 cells/mL, SLAMF7 CAR-T cells 1x10e5 cells/mL, SLAMF7 CAR-T cells 3x10e5 cells/mL, SLAMF7 CAR-T cells 1x10e6 cells/mL SLAMF7 C1 SLAMF7 CAR-T cells 3x10e4 cells/mL SLAMF7 CAR-T cells 1x10e5 cells/mL SLAMF7 C4

Overview

Phase: Phase 1/2
Intervention: Not specified
Conditions: Not specified
Sponsor: Universitaetsklinikum Wuerzburg AöR
Enrollment: 33
Locations: 1
Primary Endpoint: 1.) Phase I: Type, frequency, and severity of adverse events (AEs), including serious adverse events (SAEs), cytokine release syndrome (CRS), and neurotoxicity (i.e. immune effector cell-associated neurotoxicity syndrome [ICANS])
Status: Suspended
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

1.) Phase I: Safety determination of the treatment with SLAMF7 CAR-T; 2.) Phase I: Determination of the MTD and the recommended phase IIa dose of SLAMF7 CAR-T 3.) Phase IIa: Safety determination of the treatment with SLAMF7 CART; 4.) Phase IIa: Evaluation of the efficacy, defined as overall response rate (ORR) of SLAMF7 CAR-T in patients with MM

Registry

euclinicaltrials.eu

Start Date

January 30, 2025

End Date

TBD

Last Updated

last year

Study Type

Interventional clinical trial of medicinal product

Investigators

Sponsor

Universitaetsklinikum Wuerzburg AöR

Responsible Party

Principal Investigator

Sekretariat I

Scientific

Universitaetsklinikum Wuerzburg AöR

Eligibility Criteria

Inclusion Criteria

•Signed informed consent form.
•Patient is ≥18 years of age.
•Patient is willing and able to adhere to the protocol requirements.
•Patient is willing and able to adhere to the protocol requirements.
•Patient with diagnosis of MM who has been treated with at least 2 prior lines of treatment, including at least one cycle of high-dose chemotherapy with autologous hematopoietic stem cell transplantation if the patient was eligible, and exposure to an immunomodulatory imide drug (e.g. lenalidomide and/or pomalidomide), a proteasome inhibitor, and an anti-CD38 antibody. (Note: Induction therapy, up to 2 cycles of high-dose chemotherapy with autologous hematopoietic stem cell transplantation, and subsequent consolidation and/or maintenance therapy are considered one line of treatment).
•At least one of the following subcriteria must be measured in the patient: - Serum M-protein greater or equal to 0.5 g/dL - Urine M-protein greater or equal to 200 mg/24 h - Serum free light chain (FLC) assay: involved FLC level greater or equal to 10 mg/dL (100 mg/L) provided serum FLC ratio is abnormal - A biopsy-proven evaluable plasmacytoma - Bone marrow plasma cells >10% of total bone marrow cells (>30% if bone marrow plasma cells are the only marker of measurable disease)
•Patients previously treated with an anti-SLAMF7 antibody are eligible.
•Karnofsky performance status ≥60%. If patient has a Karnofsky performance status <60% (e.g. after a spinal cord injury) but is judged to be medically fit by the investigator, patient is eligible.
•Female patients of childbearing potential must: a) have a negative pregnancy test (blood) at screening. b) either commit to true abstinence from heterosexual contact or agree to use, and be able to comply with, effective measures of contraception without interruption, from screening through 1 year following the IMP infusion. A highly effective method of contraception or birth control (failure rate less than 1% per year when used consistently and correctly) must be practiced. The patient should be informed of the potential risks associated with becoming pregnant while enrolled in this clinical trial. Reliable methods for this trial are: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogenonly hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, sexual abstinence or vasectomized sexual partner. Abstinence is only accepted as true abstinence: when this is in line with the preferred and usual lifestyle of the patient. (Periodic abstinence [e.g. calendar, ovulation, symptothermal, post-ovulation methods and withdrawal] are not acceptable methods of contraception.) Postmenopausal (no menses for at least 1 year without alternative medical cause) or surgically sterile female patients (tubal ligation, hysterectomy or bilateral oophorectomy) may be enrolled. c) Agree to abstain from breast feeding during the study participation and for 1 year after the IMP infusion.
•Male patients must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential for at least 1 year after IMP infusion, even if he has undergone a successful vasectomy.

Exclusion Criteria

•Patient has undergone a prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤12 months prior to leukapheresis.
•Evidence of human immunodeficiency virus (HIV) infection.
•Seropositive for and with evidence of active viral infection with hepatitis B virus (HBV), excluding - Patients who are hepatitis B surface antigen negative and HBV viral deoxyribonucleic acid (DNA) negative - Patients who had hepatitis B but have received an antiviral treatment and show non-detectable viral DNA for 6 months - Patients who are seropositive because of hepatitis B virus vaccine - Patients with known HBV infection but undetectable HBV viral load and on anti-viral therapy to prevent HBV reactivation.
•Seropositive for and with active viral infection with hepatitis C virus (HCV), excluding - Patients who had hepatitis C but had received an antiviral treatment and show no detectable HCV viral ribonucleic acid (RNA) for 6 months.
•Seropositive for syphilis on treponema pallidum hemagglutination test, excluding - Patients with negative treponema pallidum antibody absorption test result
•Patients with active infection (e.g. asymptomatic and symptomatic severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] infection) or other serious medical or psychiatric disorder on investigators decision.
•Pregnant or lactating women.
•Current or previous (within 30 days of enrollment) treatment with another IMP.
•Known abuse of alcohol, drugs, or medicinal products.
•Employees of the sponsor, or employees or relatives of the investigator.

Outcomes

Primary Outcomes

1.) Phase I: Type, frequency, and severity of adverse events (AEs), including serious adverse events (SAEs), cytokine release syndrome (CRS), and neurotoxicity (i.e. immune effector cell-associated neurotoxicity syndrome [ICANS])

2.) Phase I: MTD of SLAMF7 CAR-T that can be administered in phase IIa will be assessed at the end of phase I

3.) Phase IIa: Type, frequency, and severity AEs, including SAEs, CRS, and neurotoxicity (i.e. ICANS)

4.) Phase IIa: Percentage of patients who achieved partial response (PR) or better using the IMWG Uniform Response Criteria for Multiple Myeloma at Months 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, 21 and 24 after SLAMF7 CAR-T infusion

Secondary Outcomes

1.) Phase IIa: Percentage of patients who achieved CR or better using the IMWG Uniform Response Criteria for Multiple Myeloma at Months 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, 21 and 24 after SLAMF7 CAR-T infusion
2.) Phase I and IIa: Percentage of myeloma patients enrolled into the trial who receive ex vivo expanded autologous SLAMF7 CAR-T within the 48h shelf-life of the product
3.) Phase I and IIa: Maximum peak in SLAMF7 CAR-T (Cmax), time to peak of SLAMF7 CAR-T (Tmax), area under the curve of CAR-T CD4+ and CD8+ cells (AUC), including maximum expansion and duration of persistence of SLAMF7 CAR-T cells at Baseline, Days 1, 3, 7, 10, 14, 21, 28, Week 6, 8, 12, Months 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 18, 21, 24
4.) Phase I and IIa: a) Time between first SLAMF7 CAR-T infusion and first documentation of response at Months 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, 24; b) Time between first response and disease progression PD or death at Months 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, 24 c) Time between SLAMF7 CAR-T infusion and first documentation of PD or death at Months 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, 24 d) Phase I and IIa: Proportion of minimal residual disease (MRD) evaluable patients that are MRD negativ
5.) Phase I and IIa: Time between SLAMF7 CAR-T infusion and time of death at Months 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, 24
6.) Patient-reported outcomes as measured by EORTC-QLQ-C30/-MY20 at Screening, Baseline, Months 6, 12, 24